Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159262012> ?p ?o ?g. }
- W2159262012 endingPage "350" @default.
- W2159262012 startingPage "338" @default.
- W2159262012 abstract "Transcription factors have long been deemed 'undruggable' targets for therapeutics. Enhanced recognition of protein biochemistry as well as the need to have more targeted approaches to treat cancer has rendered transcription factors approachable for therapeutic development. Since transcription factors lack enzymatic domains, the specific targeting of these proteins has unique challenges. One challenge is the hydrophobic microenvironment that affects small molecules gaining access to block protein interactions. The most attractive transcription factors to target are those formed from tumor specific chromosomal translocations that are validated oncogenic driver proteins. EWS-FLI1 is a fusion protein that results from the pathognomonic translocation of Ewing sarcoma (ES). Our past work created the small molecule YK-4-279 that blocks EWS-FLI1 from interacting with RNA Helicase A (RHA). To fulfill long-standing promise in the field by creating a clinically useful drug, steps are required to allow for in vivo administration. These investigations identify the need for continuous presence of the small molecule protein-protein inhibitor for a period of days. We describe the pharmacokinetics of YK-4-279 and its individual enantiomers. In vivo studies confirm prior in vitro experiments showing (S)-YK-4-279 as the EWS-FLI1 specific enantiomer demonstrating both induction of apoptosis and reduction of EWS-FLI1 regulated caveolin-1 protein. We have created the first rat xenograft model of ES, treated with (S)-YK-4-279 dosing based upon PK modeling leading to a sustained complete response in 2 of 6 ES tumors. Combining laboratory studies, pharmacokinetic measurements, and modeling has allowed us to create a paradigm that can be optimized for in vivo systems using both in vitro data and pharmacokinetic simulations. Thus, (S)-YK-4-279 as a small molecule drug is ready for continued development towards a first-in-human, first-in-class, clinical trial." @default.
- W2159262012 created "2016-06-24" @default.
- W2159262012 creator A5008552666 @default.
- W2159262012 creator A5010153046 @default.
- W2159262012 creator A5030736508 @default.
- W2159262012 creator A5038265237 @default.
- W2159262012 creator A5051131627 @default.
- W2159262012 creator A5066652067 @default.
- W2159262012 creator A5073277560 @default.
- W2159262012 creator A5074137694 @default.
- W2159262012 creator A5083229382 @default.
- W2159262012 date "2013-11-11" @default.
- W2159262012 modified "2023-10-13" @default.
- W2159262012 title "Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’ EWS-FLI1 transcription factor in Ewing Sarcoma" @default.
- W2159262012 cites W1760321613 @default.
- W2159262012 cites W1907083095 @default.
- W2159262012 cites W1967700202 @default.
- W2159262012 cites W1968324646 @default.
- W2159262012 cites W1971803615 @default.
- W2159262012 cites W1972859280 @default.
- W2159262012 cites W1973359795 @default.
- W2159262012 cites W1979641354 @default.
- W2159262012 cites W1980480652 @default.
- W2159262012 cites W1990200822 @default.
- W2159262012 cites W1991525638 @default.
- W2159262012 cites W2007438323 @default.
- W2159262012 cites W2027704988 @default.
- W2159262012 cites W2042380110 @default.
- W2159262012 cites W2055644676 @default.
- W2159262012 cites W2066962978 @default.
- W2159262012 cites W2072315137 @default.
- W2159262012 cites W2074688911 @default.
- W2159262012 cites W2082964850 @default.
- W2159262012 cites W2084652316 @default.
- W2159262012 cites W2088180120 @default.
- W2159262012 cites W2090309636 @default.
- W2159262012 cites W2101854267 @default.
- W2159262012 cites W2115230264 @default.
- W2159262012 cites W2122260140 @default.
- W2159262012 cites W2128628566 @default.
- W2159262012 cites W2143176313 @default.
- W2159262012 cites W2161680149 @default.
- W2159262012 cites W2170213020 @default.
- W2159262012 cites W2317345315 @default.
- W2159262012 cites W2886499456 @default.
- W2159262012 doi "https://doi.org/10.18632/oncotarget.1495" @default.
- W2159262012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3964211" @default.
- W2159262012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24481407" @default.
- W2159262012 hasPublicationYear "2013" @default.
- W2159262012 type Work @default.
- W2159262012 sameAs 2159262012 @default.
- W2159262012 citedByCount "37" @default.
- W2159262012 countsByYear W21592620122014 @default.
- W2159262012 countsByYear W21592620122015 @default.
- W2159262012 countsByYear W21592620122016 @default.
- W2159262012 countsByYear W21592620122017 @default.
- W2159262012 countsByYear W21592620122018 @default.
- W2159262012 countsByYear W21592620122019 @default.
- W2159262012 countsByYear W21592620122020 @default.
- W2159262012 countsByYear W21592620122021 @default.
- W2159262012 countsByYear W21592620122022 @default.
- W2159262012 countsByYear W21592620122023 @default.
- W2159262012 crossrefType "journal-article" @default.
- W2159262012 hasAuthorship W2159262012A5008552666 @default.
- W2159262012 hasAuthorship W2159262012A5010153046 @default.
- W2159262012 hasAuthorship W2159262012A5030736508 @default.
- W2159262012 hasAuthorship W2159262012A5038265237 @default.
- W2159262012 hasAuthorship W2159262012A5051131627 @default.
- W2159262012 hasAuthorship W2159262012A5066652067 @default.
- W2159262012 hasAuthorship W2159262012A5073277560 @default.
- W2159262012 hasAuthorship W2159262012A5074137694 @default.
- W2159262012 hasAuthorship W2159262012A5083229382 @default.
- W2159262012 hasBestOaLocation W21592620121 @default.
- W2159262012 hasConcept C104317684 @default.
- W2159262012 hasConcept C123894998 @default.
- W2159262012 hasConcept C138885662 @default.
- W2159262012 hasConcept C161624437 @default.
- W2159262012 hasConcept C179926584 @default.
- W2159262012 hasConcept C185592680 @default.
- W2159262012 hasConcept C207001950 @default.
- W2159262012 hasConcept C2777937962 @default.
- W2159262012 hasConcept C40767141 @default.
- W2159262012 hasConcept C41895202 @default.
- W2159262012 hasConcept C502942594 @default.
- W2159262012 hasConcept C54355233 @default.
- W2159262012 hasConcept C70721500 @default.
- W2159262012 hasConcept C86339819 @default.
- W2159262012 hasConcept C86803240 @default.
- W2159262012 hasConcept C95444343 @default.
- W2159262012 hasConcept C98274493 @default.
- W2159262012 hasConceptScore W2159262012C104317684 @default.
- W2159262012 hasConceptScore W2159262012C123894998 @default.
- W2159262012 hasConceptScore W2159262012C138885662 @default.
- W2159262012 hasConceptScore W2159262012C161624437 @default.
- W2159262012 hasConceptScore W2159262012C179926584 @default.
- W2159262012 hasConceptScore W2159262012C185592680 @default.
- W2159262012 hasConceptScore W2159262012C207001950 @default.
- W2159262012 hasConceptScore W2159262012C2777937962 @default.